Vanguard Portfolio Management
RLMD icon

Vanguard Portfolio Management’s Relmada Therapeutics RLMD Stock Holding History

Vanguard Portfolio Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.22M Buy
+898,198
New +$6.28M ﹤0.01% 2373

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management's RLMD Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 898,198 shares worth $6.22M. The stake represents ﹤0.01% of the portfolio and ranks #2373 among its holdings.

126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Vanguard Portfolio Management held 898,198 shares of Relmada Therapeutics worth $6.22M as of Q2 2026.
  • Relmada Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2373 holding.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.